The Clinical Trial,

The leaps we’re helping to deliver in research and innovation that inform better patient outcomes wouldn’t be possible without our deep partnerships with researchers and clinicians across all sectors of the healthcare landscape including: university, pharma, community health, and more.

I-SPY Family of Trials

The I-SPY series of trials are changing the way new treatments are developed, helping make available new, better and more personalized treatments, faster.

The ground-breaking I-SPY 2 trial of neoadjuvant treatment for locally advanced breast cancer , employing an 'adaptive' clinical trial model designed to increase trial efficiency by minimizing the number of participants and time required to evaluated an experimental agent.
I-SPY Phase 1b is an open-label platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients.
This trial focuses on identifying agents that can reduce mortality and the need for, as well as the duration of, mechanical ventilation or advanced respiratory support in patients with Acute Respiratory Distress Syndrome (ARDS).
Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer by evaluating three investigational endocrine therapy arms.

I-SPY 2 Data

Download all the latest data and findings from our ongoing I-SPY 2 trials.


Interested in QLHC related research? Find the links here.


A thorough collection of useful research and data resources.

I-SPY 2 Leadership

Meet the leading minds leading our innovative cancer trials.

Partner With Us

Discover all the ways leading research organizations are partnering with us to deliver faster innovations in research and patient therapies.

I-SPY Clinical Sites

A collaborative network of partners helping us change the game in cancer care.

News Coverage

A collection of announcements and press releases related to Investigators

40-site U.S. trial enrolling more than 300 patients could significantly change the way DCIS is treated and reduce possibly unnecessary surgery
Quantum Leap Healthcare Collaborative™ today announced that Arvinas’ vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.
Exai Bio today announced a collaboration agreement with Quantum Leap Healthcare Collaborative™ (QLHC) to expand the use of Exai’s novel, RNA-based liquid biopsy platform to monitor patients’ treatment response and disease burden in the I-SPY 2 TRIAL. I-SPY2 is the largest and longest-running 'platform' trial that provides a regulatory framework to study multiple novel therapeutic treatment arms for women with newly diagnosed, locally advanced breast cancer. 
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, and Quantum Leap Healthcare Collaborative™ today announce that Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM),(Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2clinical trial.
Contact Us
Investigators Portal
QLHC in the News
Working at QL
Contact Us